



April 8, 2020  
Gene Techno Science Co., Ltd.  
Code: 4584 (TSE Mothers)  
Masaharu Tani, President & CEO

## **Announcement of completion of issuance of the 3rd series of convertible bond with stock acquisition rights and the 10th series of stock acquisition rights**

Tokyo, April 8, 2020 – Gene Techno Science Co., Ltd. (“GTS”) completed the issuance of the 3rd series of convertible bond with stock acquisition rights and the 10th series of stock acquisition rights to CVI Investments, Inc. and confirmed the payment of the fund. This fund will be used mainly for promoting JRM-001 aiming at improving cardiac functions on post-surgery. (This project will be led by Japan Regenerative Medicine Co., Ltd. which is now a 100% affiliate of GTS.)

### 1. Overview of the 3rd series of convertible bond with stock acquisition rights

Closing Date	April 8, 2020
Number of issuance	30 units
Issue amount	Convertible bond : JPY600,000,000 No payment is required in exchange for stock acquisition rights.
Conversion price	Reference price: JPY479 Floor price: JPY240
Number of dilutive shares	1,252,609 shares
Total amount of funds procured	JPY600,000,000
Terms and conditions for price adjustment	9 months after the closing date, and semiannually thereafter, the conversion price will be adjusted to the lesser of either; (i) 91% of the then prevailing market price, the average of the two lowest volume weighted average prices for the common shares during the 15 trading day period immediately preceding the applicable date or (ii) the prevailing conversion price on the CB adjustment date. However, if the adjusted conversion price on the CB adjustment date falls below the minimum conversion price, the conversion price will be the minimum conversion price.
Issuing Method	CVI Investments, Inc.
Coupon/ Timeline	0% / Maturity Date: July 31, 2023
Redemption price	JPY100 per face value of JPY100

## 2. Overview of the 10th series of stock acquisition rights

Closing Date	April 8, 2020
Number of issuance	16,284 units
Issue amount	JPY298 per stock acquisition right
Exercise price	Reference price: JPY479 Floor price: JPY240
Number of dilutive shares	1,628,400 shares
Total amount of funds procured	JPY780,003,600*
Terms and conditions for price adjustment	9 months after the closing date, and semiannually thereafter, the conversion price will be adjusted to the lesser of either; (i)90% of the then prevailing market price, the average of the two lowest volume weighted average prices for the common shares during the 15 trading day period immediately preceding the applicable date or (ii) the prevailing exercise price on the effective date of the subscription rights. However, if the price calculated by the above amendment is lower than the minimum exercise price, the adjusted amount will be the minimum exercise price.
Issuing Method	CVI Investments, Inc.

\*Note: The total amount is assumed that all of the stock acquisition rights have been exercised at the initial exercise price. If the exercise price is modified or adjusted, the amount will be reduced. If the stock acquisition rights are not exercised during the exercise period, or if our stock acquisition rights are canceled, the amount will decrease.

About Gene Techno Science Co., Ltd. GTS announced GTS 3.0 “Biotech Engineering Company, striving for value creation” a new business stage starting from this fiscal year, which targeted the pediatric disease in addition to the areas GTS has been engaged in such as the orphan disease and intractable disease. By leveraging the knowhow and expertise about biotechnology acquired in the past business activities, GTS is working on the development and provision of new medicines and therapeutic treatment for the purpose of achieving comprehensive healthcare solutions for the patients suffering from these diseases as well as families and caregivers.

### Contact:

Gene Techno Science Co., Ltd.

Tel: +81-3-6222-9547 Mail: [info@g-gts.com](mailto:info@g-gts.com)